High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.

Tyrosine kinase inhibitors (TKIs) have revolutionized the management of patients with chronic myelogenous leukemia (CML); however, they may cause cardiovascular (CV) toxicities. In this cross-sectional study, we explored whether high-sensitivity C-reactive protein (hsCRP) and novel markers of vascular dysfunction were associated with exposure to specific TKIs, in 262 CML patients. Hs-CRP level was not associated with CML disease activity or treatment with a specific TKI. Body mass index (OR: 1.15, 95% CI: 1.108-1.246; p < 0.001) and CML duration (OR: 1.004, 95% CI: 1.001-1.008; p = 0.024) were independently associated with higher hs-CRP. In exploratory analyses, novel endothelial-centric markers (e.g. ET-1 and VCAM-1) were differential across the various TKIs, particularly amongst nilotinib- and ponatinib-treated patients. While Levels of hs-CRP do not appear to be correlated with specific TKIs, circulating markers of vascular dysfunction were altered in patients treated with specific TKIs and should be explored as potential markers of TKI-associated CV risk.

[1]  C. Marzano,et al.  Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) , 2021, Frontiers in Oncology.

[2]  G. Francis,et al.  2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. , 2021, The Canadian journal of cardiology.

[3]  M. Nurmohamed,et al.  Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice , 2021, Heart.

[4]  G. Pond,et al.  Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease , 2021, Heart.

[5]  J. Fish,et al.  Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia , 2020, Current Hematologic Malignancy Reports.

[6]  P. Libby,et al.  Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease , 2019, Nature Reviews Cardiology.

[7]  O. McCarty,et al.  Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. , 2019, Blood.

[8]  M. Hofmann,et al.  Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation , 2018, Front. Cardiovasc. Med..

[9]  Jacob D. Jaffe,et al.  A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML. , 2018, Blood advances.

[10]  J. Jukema,et al.  The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model , 2018, Front. Cardiovasc. Med..

[11]  J. Lipton,et al.  Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long‐term Follow‐up , 2017, Clinical lymphoma, myeloma & leukemia.

[12]  G. Superti-Furga,et al.  Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site , 2017, Leukemia.

[13]  T. Ikezoe,et al.  The BCR/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1β in vascular endothelium in association with downregulation of miR-3p. , 2017, Leukemia research.

[14]  D. Lev,et al.  Ponatinib reduces viability, migration, and functionality of human endothelial cells , 2017, Leukemia & lymphoma.

[15]  M. Baccarani,et al.  Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion , 2017, Annals of Hematology.

[16]  Praveen Shukla,et al.  High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells , 2017, Science Translational Medicine.

[17]  C. Chai-Adisaksopha,et al.  Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis , 2016, Leukemia & lymphoma.

[18]  D. Steensma,et al.  Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors. , 2015, Journal of the American College of Cardiology.

[19]  P. Valent,et al.  Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. , 2015, Blood.

[20]  M. Baccarani,et al.  Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial. , 2014 .

[21]  Francisco Cervantes,et al.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.

[22]  F. Giles,et al.  Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis , 2013, Leukemia.

[23]  B. Dörken,et al.  Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib , 2013, Leukemia.

[24]  B. Dörken,et al.  Clinical cardiac safety profile of nilotinib , 2012, Haematologica.

[25]  B. Dörken,et al.  Severe peripheral arterial disease during nilotinib therapy. , 2011, Journal of the National Cancer Institute.

[26]  G. Szot,et al.  Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice , 2008, Proceedings of the National Academy of Sciences.

[27]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[28]  G. Garcı́a-Cardeña,et al.  Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis. , 2013, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.